The Anglo-Scandinavian Cardiac Outcomes Trial-LipidLowering Arm (ASCOT-LLA) trial demonstrated the benefits of combined antihypertensive/lipid-lowering treatment over antihypertensive treatment alone in hypertensive patients with X3 additional cardiovascular (CV) risk factors. We assessed the prevalence and treatment of patients with hypertension and X3 additional CV risk factors in The Netherlands and Italy in a retrospective cohort study using the This study shows that primary prevention of CVD in hypertensive patients in The Netherlands and Italy could be improved.
Introduction
Cardiovascular disease (CVD) is the leading cause of mortality worldwide, accounting for 30% of all deaths (16.7 million each year). [1] [2] [3] In Europe, nearly half of all deaths (49%) are attributable to CVD. 4 Cardiovascular (CV) risk factors rarely occur in isolation and most patients have a combination of risk factors, which contribute to their absolute risk of CVD (that is, the probability that a patient will have a CV event in a defined period). 5 Data from observational studies indicate that concomitant CV risk factors generally exert a synergistic effect on the risk of developing a CV event. 6, 7 Hypertension (HTN) represents the leading risk factor for CVD mortality 8 and the risk of CVD increases continuously with increasing elevated blood pressure (BP) levels. 9, 10 Alongside HTN, dyslipidaemia represents an important modifiable risk factor. It has been shown that dyslipidaemia is more frequently present in hypertensive than in normotensive individuals. [10] [11] [12] [13] This association may indicate a common cause or the presence of aggravating factors for both high BP and high cholesterol. [11] [12] [13] The pattern of risk factors for CVD denotes that the disease is not merely a consequence of old age, but rather the culmination of multiple damaging events that develop over several decades.
Considering the interplay observed between the multiple risk factors for CV, it follows that to optimize patient care, it is important to undertake a thorough assessment of total CV risk for a given individual. Accordingly, various international management guidelines for CVD now recommend addressing the global risk of CVD in a patient, rather than individual risk factors. 14, 15 In view of the complex aetiology of CVD, optimal management is likely to involve a multifactorial intervention strategy and studies have demonstrated that managing multiple risk factors is an effective way to reduce CVD risk. 16 The Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA) demonstrated significant benefits of combined antihypertensive and lipid-lowering treatment over antihypertensive treatment alone in patients with HTN and X3 additional CV risk factors. 17 Little is currently known about the prevalence of patients with HTN who have multiple concomitant CV risk factors. Considering recent insights into the treatment strategies for these patients, there is a need to have a more thorough understanding of both the prevalence and the patterns of treatment for this type of patients in a real world primary care setting.
The aim of this study was to provide an insight into the prevalence and the current management of CVD among patients with HTN and additional risk factors in the Dutch and Italian primary care settings.
Patients and methods
We conducted a retrospective cohort study with repeated retrospective assessments on 1 January of each study year using two databases containing general practitioner (GP) medical records. The objective was to assess the prevalence and treatment of hypertensive patients with X3 additional CV risk factors using primary care patient records in The Netherlands and Italy.
Databases and study populations-Integrated Primary Care Information Project database (IPCI)
For the Dutch study, patient data were obtained from the IPCI project database, a population-based, general practice research database containing data from computer-based medical records of patients registered with 150 Dutch GPs. 18, 19 In the Dutch healthcare system, the GP plays a pivotal role by acting as a gatekeeper for all medical care. All residents of The Netherlands are registered with a GP independent of their health status. The database contains the records of more than 600 000 patients, whose gender and age distributions are comparable with the entire Dutch population. 18 Information is entered into computer by the GPs and includes patient demographics, general notes, prescriptions, physical findings and laboratory findings. 18, 19 Coding of prescriptions is performed according to the Anatomical Therapeutic Chemical (ATC) classification scheme recommended by the World Health Organization. The system complies with European Union guidelines on the use of medical data for medical research and has been proven valid for pharmacoepidemiological research. 18, 19 To maximize completeness of the data, GPs participating in the IPCI project are not permitted to maintain a system of paper-based records in addition to the electronic medical records. Many peer-reviewed publications on drug safety and effectiveness, drug utilisation (including antihypertensives) and occurrence of disease based on the IPCI database have been published (www.ipci.nl). The Scientific and Ethical Advisory Board of the IPCI project approved this study.
Health Search/Thales Database (HSD)
The Italian study used the HSD, a longitudinal observational database that is representative of the entire Italian population. It was established in 1998 by the Italian College of GPs. 20 The HSD contains data from the computer-based patient records from a selected group of GPs distributed across Italy who voluntarily agreed to collect data for the database and attend specified training courses. 20 The database contains information on the age, gender and identification of the patient, and GP registration information, which is linked to the prescription information, clinical events and diagnoses, hospital admission and causes of death. All diagnoses are coded according to the International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM). Drug names are coded according to the ATC classification system. To be included in the study, GPs needed to be registered with the database for at least 1 year and meet standard quality criteria pertaining to the levels of coding, prevalence of well-known diseases and mortality rates. 20, 21 The HSD complies with European Union guidelines on the use of medical data for research. The HSD has been the source for a number of peer-reviewed publications on the prevalence of disease conditions, 21, 22 drug safety 23 and prescription patterns [24] [25] [26] [27] [28] in Italian primary care. This study was approved by the Italian College of Primary Care Physicians. Patients included in both the Dutch and Italian studies were X16 years of age with at least 1 year of valid database history. The studies were conducted between January 2000 and January 2003. Patients were followed from the date of eligibility until the end of the study period, unless death or transferral out of the practice preceded study termination, or until the date of the patient's last available data. During the follow-up period for each patient, characteristics were assessed retrospectively on 1 January of each study year.
Identification of CV risk factors
Patients were identified as having HTN if they had received such a diagnosis from a GP or specialist, if they had two or more abnormal BP measurements (4140/90 mmHg) or were receiving treatment with antihypertensive drugs specifically to treat HTN (that is, if drug was prescribed for other indications, it did not qualify as HTN proxy) (thiazides, b-blockers, calcium channel blockers (CCBs), angiotensin-converting enzyme (ACE) inhibitors or angiotensin-II receptor antagonists).
Cardiovascular risk factors in addition to HTN were identified on 1 January of each calendar year. The following CV risk factors were identified from patient records (based on the ASCOT criteria): 17, 29 Aged X55 years Total cholesterol 45 mmol l À1 (193 mg per 100 ml) Male gender Smoker History of transient ischaemic attack or stroke Peripheral arterial disease (for the IPCI only) Type 2 diabetes mellitus Proteinuria Left ventricular hypertrophy Family history of coronary heart disease.
The existence of prior recorded symptomatic CVD (myocardial infarction, angina, ischaemic stroke, transient ischaemic attack and peripheral arterial disease) was obtained from the coded diagnoses and medication use (use of nitrates).
Pharmacological treatment
Prescription records for all cohort members were retrieved from the automated files.
For those patients with X3 concomitant CV risk factors in addition to HTN and no recorded symptomatic CVD, treatment with antihypertensive (thiazides, b-blockers, CCBs, ACE inhibitors or angiotensin-II receptor antagonists) and/or lipidlowering agents (statins or other lipid-lowering agents) were assessed for each calendar year based on prescription patterns.
Blood pressure goal attainment Attainment of BP goals was calculated in the following two ways: for the stringent measure, all BP measurements in the subsequent calendar year were required to be o140/90 mmHg in line with World Health Organization recommendations; for the less stringent measure, patients were considered to be at goal, if they had at least one BP measurement o140/90 mmHg in the subsequent year.
Statistical analysis
Prevalence rates of HTN were calculated by dividing the number of patients with HTN by the population on the 1 January of each calendar year. Prevalence of risk factors in patients with HTN were based on the presence of these CV risk factors in the period before the assessment date (1 January of each calendar year). In case the information on a specific risk factor (for example, smoking) was not present, we considered the patient not to have that condition/ risk factor. The denominator for calculation of risk factor prevalence was patients with recorded HTN before the assessment date. Changes in prevalence rates were calculated by comparison of proportions. Po0.05 was considered statistically significant.
The population for assessment of BP goal attainment in 1 year comprised all patients with HTN on 1 January preceding the follow-up year, who had at least one recorded BP measurement during the subsequent follow-up year. Patients without the recorded BP measurements were not included in the percentage calculations.
Results

Study population
The quality criteria were met by 320 GPs and their data were included in this study. In the Dutch IPCI, the source population comprised approximately 175 000 patients aged X16 years (mean age: 45 years) who had 1 year of valid documented medical history; approximately half of this population was male (49.4%; Table 1 ). In the Italian HSD, the source population consisted of approximately 325 000 patients aged X16 years (mean age: approximately 49 years) and 1 year of valid history; of these, 47.6% were male (Table 1) .
Disease prevalence
The prevalence of recorded HTN in the Dutch study population increased from 20.3 to 22.3% between 2000 and 2002 (a relative increase of 9.8% (Po0.001)) and the prevalence of recorded CVD increased from 4.0 to 5.4% over the same time period (Po0.001; Table 1 ). In the Italian study population, the prevalence of recorded HTN increased from 19.0 to 21.8% (a relative increase of 14.7% (Po0.001)) and the prevalence of recorded CVD increased from 3.1 to 3.7% over the study period (a relative increase of 19.4% (Po0.001); Table 1 ). Approximately 20% of Dutch hypertensive patients and 16% of Italian hypertensive patients had prior recorded symptomatic CVD.
The prevalence of patients with X3 additional CV risk factors among those with HTN increased from 31.2% in 2000 to 34.2% in 2002 for the Dutch population (Po0.001; Figure 1a and Table 2 ) and from 31.1 to 39.3% for the Italian population (Po0.001; Figure 1b and Table 2 ) over the same period. Among these patients, the most frequently recorded additional risk factors were the same across the two populations: aged X55 years, male gender and total cholesterol 45 mmol l À1 (193 mg per 100 ml; Table 2 ). The distribution of CV risk factors in addition to HTN in patients with X3 CV risk factors was similar across each year of the study period for the two study populations (Table 2) . Of note was the increase in female patients in the Italian data set and an increase in the abnormal total cholesterol levels, whereas a decrease in the percentage of patients with abnormal total cholesterol in those with X3 additional CV risk factors was seen in the Dutch data set. Approximately one-third of hypertensive patients with X3 additional CV risk factors in the Dutch population and one-quarter of those with the same profile in the Italian population had prior recorded symptomatic CVD.
Pharmacological treatment
Among the hypertensive patients with X3 concomitant CV risk factors but no prior CVD (63% and 75% of the total Dutch and Italian database populations, respectively) approximately 54-57% received antihypertensive treatment in the Dutch population (Figure 2a ), compared with a much higher 80% in the Italian population (Figure 2b ). This percentage decreased slightly from 2000 to 2002, from 83.2 to 80.3% (Po0.05). In the Dutch population, the most frequently used antihypertensive agents were b-blockers, followed by ACE inhibitors and CCBs. This order of antihypertensive use remained the same over the 3-year study period, although the use of angiotensin-II antagonists increased slightly from 15 to 18% from 2000 to 2002 (Po0.05). In the Italian population, the most frequently used antihypertensive agents were ACE inhibitors, CCBs and b-blockers.
Among hypertensive patients with X3 concomitant CV risk factors and no prior symptomatic CVD, 21-24% of those in the Dutch population (Figure 2a) and 17-20% in the Italian population (Figure 2b ) received lipid-lowering medications.
A small increase in the use of concomitant antihypertensive and lipid-lowering medications among patients with HTN and X3 additional CV risk factors and no prior symptomatic CVD was observed over time, from 14.2 to 17.6% in the Dutch population (Po0.05; Figure 2a ) and from 15.5 to 17.4% in the Italian population (Po0.05; Figure 2b ) during the 3-year study period.
Blood pressure goal attainment
Approximately 35-36% of the hypertensive patients with X3 additional CV risk factors and no prior symptomatic CVD had on average no BP measurement during each year of the study in the Dutch population compared with 30% of Italian patients with the same profile.
In both populations, BP goal attainment was low, but fewer patients in the Dutch population than in the Italian population attained BP goal. Using the stringent approach, 20 vs 30% of patients had all BP measurements o140/90 mmHg during each study year in the Dutch and Italian populations, respectively (Figures 3a and b) . Half the Dutch patients and more than 70% of Italian patients had at least one BP measurement o140/90 mmHg (less stringent measure) during each study year (Figures 3a and b) .
Discussion
In both the IPCI and HSD populations, approximately one-third of hypertensive patients had X3 31 The reasons for this rapid rise in the prevalence of hypertensive patients with multiple risk factors over this short period is likely to be related to the increased cholesterol screening in practices. Certainly within both the Dutch and the Italian populations, screening for HTN and other CV risk factors increased between 2000 and 2002, as detailed in our publications elsewhere. 32 Interestingly, the use of antihypertensive medication was considerably higher in the HSD compared with the IPCI population (80-83% vs 54-57%, respectively). A high treatment rate of HTN in the Italian population compared with treatment rates in other European countries is confirmed by a comparative analysis of sample surveys investigating levels of HTN treatment and control in Europe, the United States and Canada. 33 In this report, Italy had the highest age-adjusted treatment rates for HTN among the five European countries studied at both the 160/95 mmHg and the 140/90 mmHg thresholds. 33 The Netherlands were not included in this analysis. The use of lipid-lowering medication was slightly higher in patients in the IPCI compared to patients in the HSD population (21-24 vs 17-20%, respectively).
Goal attainment for BP was higher in the Italian than in the Dutch population, using both the stringent (29-36 vs 18-20%) and the less stringent approach (74-76 vs 46-48%). This may be due to different treatment targets (earlier guidelines in The Netherlands recommended the 160/90 mmHg threshold), differences in the type of dose being used and persistence with antihypertensive agents. For example, a larger percentage of ACE inhibitors, CCBs and combination therapy were used in the HSD. A regimen with an ACE inhibitor and a CCB was shown to be more potent than a b-blocker-based regimen in the BP lowering arm of the ASCOT trial (ASCOT-BPLA). 34 These data highlight that GPs who manage hypertensive patients in primary care settings are very likely to encounter patients who have multiple concomitant risk factors for CVD in addition to HTN. As the number of hypertensive patients worldwide is on the increase, the number of cases of HTN with X3 additional risk factors managed by GPs is also likely to rise. An analysis of worldwide data estimated that one-quarter of the world's adult population had HTN in 2000 and that this proportion is set to increase to 29% by 2025-a total of 1.56 billion people. 8 The high prevalence of HTN has contributed to the current pandemic of CVD, which has latterly become one of the major contributors to the global burden of disease.
Our study has added support to the notion that the treatment of hypertensive patients in The Netherlands and Italy could be improved, given the current level of evidence. Despite the high prevalence of hypertensive patients with multiple modifiable CV risk factors in these populations, less than 17-18% were being treated with concomitant antihypertensive and lipid-lowering therapies. In the IPCI, approximately 54-57% of these patients received antihypertensive treatment and 21-24% received lipid-lowering medication. In the HSD, approximately 80-83% of these patients received antihypertensives and 17-20% received lipid-lowering drugs. National cholesterol guidelines at the time the study was conducted recommended pharmacological treatment only in patients at a higher risk (that is, a 10-year Framingham risk for CVD of 420% in patients without CVD), 35 which may explain the lower treatment rates with lipid-lowering therapy compared with antihypertensive therapy observed in this study. The findings in this study were similar to those reported for a UK population where over 30% of hypertensive patients with X3 additional CV risk factors did not receive any antihypertensive medication. 31 It is also possible that patients may have been reluctant to initiate lipid-lowering therapy, particularly when they were already taking multiple medications for other CV risk factors. Furthermore, clinicians may have encouraged their patients to initiate therapeutic lifestyle changes before instigating lipid-lowering medications, particularly in patients with mild dyslipidaemia.
As demonstrated in the ASCOT-LLA trial, 17 hypertensive patients with X3 additional CV risk factors may benefit from treatment with lipid-lowering medication, although some of them may have a 10-year CVD risk o20% and would therefore not have been eligible for treatment at the time the study was conducted. One method to help GPs achieve better rates of treatment and control of CV risk factors is to provide clear and appropriate guidelines. In recent years, CV management guidelines worldwide have moved towards an integrated approach to the reduction of overall CV risk by treating both BP and lipids as well as other CV risk factors. 15, 36 This global approach should translate into better treatment and control rates at the national level in the years to come.
Limitations and validity
This study utilized observational databases to assess recorded disease prevalence and treatment patterns in The Netherlands and Italy. This is useful in that it provides a true picture of GP activities in these countries. However, such an approach confers a number of limitations. For example, not all CV risk factors are screened and recorded for all patients by their GPs. Therefore, this is likely to lead to an underestimation of the prevalence of HTN and/or hypercholesterolaemia and therefore an underestimation of the patients requiring treatment for these conditions. Furthermore, incomplete information on patient's smoking habits and assumptions regarding the presence of familial hypercholesterolaemia will have resulted in an underestimation of the number of patients eligible for treatment. This, coupled with the fact there may be patients with elevated cholesterol and/or BP levels whose condition has not been recognized by their GP, or who have not visited their GP, may mean that the rate of undertreatment is likely to be higher than reported here. Conversely, it is also likely that some of the patients with recorded HTN may have actually had white-coat HTN and thus presented with BP readings of 4140/90 mmHg in the physician's surgery, but which would have fallen to p140/90 mmHg after leaving the office. Controlling for white-coat HTN is beyond the scope of this study. The misdiagnosis of patients with white-coat HTN is likely to be a limitation of all studies of the prevalence of HTN that utilize GP office/clinic readings of BP rather than those made at home or using ambulatory BP monitoring. Moreover, given that the risk factors frequently cluster in individual patients with X3 CV risk factors, it would seem likely that these patients have true HTN rather than white-coat HTN. Furthermore, some studies have suggested that patients with white-coat HTN go on to develop HTN. 37, 38 Our findings suggest that many patients with HTN and X3 additional risk factors for CVD are undertreated according to the current level of evidence. Hence, there is considerable potential to improve the treatment of patients with HTN. New treatment strategies are needed to help further the prevention of CV events, particularly for hypertensive patients who have additional CV risk factors. Studies such as this, which investigate the prevalence of CV risk factors, are an important source of primary information for the planning of national health services. These data also add to the picture of the global burden of CVD, which in turn help international public health policy makers assign proper priority to this critical health threat.
